Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies

BACKGROUND: IDH-wildtype glioblastoma (GBM) is a highly malignant primary brain tumor with a median survival of 15 months after standard of care, which highlights the need for improved therapy. Personalized combination therapy has shown to be successful in many other tumor types and could be benefic...

Descripción completa

Detalles Bibliográficos
Autores principales: Houweling, Megan, Giczewska, Anna, Abdul, Kulsoom, Nieuwenhuis, Ninke, Küçükosmanoglu, Asli, Pastuszak, Krzysztof, Buijsman, Rogier C, Wesseling, Pieter, Wedekind, Laurine, Noske, David, Supernat, Anna, Bailey, David, Watts, Colin, Wurdinger, Thomas, Westerman, Bart A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347974/
https://www.ncbi.nlm.nih.gov/pubmed/37455945
http://dx.doi.org/10.1093/noajnl/vdad073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347974/
https://www.ncbi.nlm.nih.gov/pubmed/37455945
http://dx.doi.org/10.1093/noajnl/vdad073

Ejemplares similares